Abstract
Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for short-term obesity treatment in conjunction with lifestyle modifications, but is commonly used chronically. Topiramate, approved for treating epilepsy and preventing migraines, also induces weight loss. A single-dose combination of low-dose phentermine and topiramate extended-release was recently approved by the United States Food and Drug Administration as an adjunct to lifestyle intervention for the chronic treatment of overweight/obese adults. This review summarizes and evaluates the cardiovascular risk/benefit profile associated with phentermine and topiramate, individually and in combination. Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Hypertension |
| Vol/bind | 32 |
| Udgave nummer | 6 |
| Sider (fra-til) | 1178-1188 |
| Antal sider | 11 |
| ISSN | 0263-6352 |
| DOI | |
| Status | Udgivet - jun. 2014 |
FN’s Verdensmål
Dette resultat bidrager til følgende verdensmål
